



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

September 7, 2021

Yulin Wang  
Chief Executive Officer  
Meihua International Medical Technologies Co., Ltd.  
88 Tongda Road, Touqiao Town  
Guangling District, Yangzhou, 225000  
People's Republic of China

**Re: Meihua International Medical Technologies Co., Ltd.  
Amendment No. 1 to  
Registration Statement on Form F-1  
Filed August 31, 2021  
File No. 333-258659**

Dear Mr. Wang:

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our August 24, 2021 letter.

Amendment No. 1 to Form F-1 filed August 31, 2021

Intellectual Property, page 88

1. We note your response to our prior comment 6. Please expand your disclosure of the material terms of the collaboration agreement, where appropriate, to specify the nature and scope of the patent, the duration of the agreement and royalty term, termination provisions and the aggregate amounts paid or received to date under the agreement (including any up-front fees), as applicable. Please also specify the type of patent protection, expected expiration date and applicable jurisdiction of the patent.

Yulin Wang  
Meihua International Medical Technologies Co., Ltd.  
September 7, 2021  
Page 2

You may contact Tracey Houser at 202-551-3736 or Brian Cascio at 202-551-3676 if you have questions regarding comments on the financial statements and related matters. Please contact Jane Park at 202-551-7439 or Celeste Murphy at 202-551-3257 with any other questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Joe Laxague, Esq.